Isolating Fetal Neuronal Extracellular Vesicles via Two-Step Immunoprecipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating fetal neuronal extracellular vesicles from maternal blood are invasive, non-specific, and non-sensitive, making it challenging to assess fetal brain development and predict developmental disabilities.
Innovation Solution
A two-step immunoprecipitation technique using antibodies against pregnancy-specific beta-1-glycoprotein 1 (PSG1) and synaptic vesicle glycoprotein 2B (SV2B) to isolate fetal neuronal extracellular vesicles from maternal blood, allowing for quantitative measurement of synaptic function and synapse development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional isolation methods are used to obtain fetal EVs-EXs from maternal blood, then the isolation process is simple, but the specificity is low due to contamination with maternal EVs-EXs and non-neuronal cell EVs-EXs
Solution Approach 1:
The isolation process is divided into multiple sequential steps: first isolating fetal-originated EVs-EXs using anti-PSG1 antibodies, then further purifying neuronal EVs-EXs from the fetal fraction using anti-SV2B antibodies. This segmentation allows each step to target specific markers, progressively enriching for the desired fetal neuronal EVs-EXs while removing contaminating maternal and non-neuronal EVs-EXs.
Solution Approach 2:
The patent uses antibody-beaded resin complexes as intermediaries to facilitate specific binding and separation. The antibodies (anti-PSG1 and anti-SV2B) are conjugated to beaded resin, creating intermediary structures that selectively capture target EVs-EXs from the complex maternal blood mixture, enabling high-specificity isolation without direct manipulation of the EVs themselves.
2Measurement precision
If fetal brain specimens are obtained directly during pregnancy, then the assessment of fetal brain development is accurate, but the procedure becomes invasive and challenging
Solution Approach 1:
Instead of obtaining actual fetal brain tissue through invasive procedures, the patent isolates and analyzes EVs-EXs that are naturally secreted by fetal neurons into the maternal bloodstream. These extracellular vesicles serve as non-invasive copies or proxies that contain molecular information about fetal neuronal development, allowing accurate assessment without direct fetal tissue sampling.
Solution Approach 2:
The patent uses EVs-EXs as intermediary carriers that transport fetal neuronal information from the fetus to the maternal circulation. By analyzing these intermediary vesicles in maternal blood, the method indirectly accesses fetal brain development information without requiring direct fetal specimen collection, thus maintaining ease of operation while ensuring assessment accuracy.
3Ease of operation
If maternal blood is used as the source material, then the isolation procedure is non-invasive, but the quantity of fetal neuronal EVs-EXs is insufficient for quantitative measurements
Solution Approach 1:
The patent employs a two-stage enrichment strategy that segments the isolation process: first concentrating fetal-originated EVs-EXs from the large volume of maternal blood using anti-PSG1 antibodies, then further concentrating neuronal EVs-EXs from the fetal fraction using anti-SV2B antibodies. This segmented approach progressively increases the quantity of target fetal neuronal EVs-EXs from an initially dilute source while maintaining the non-invasive nature of using maternal blood.
Solution Approach 2:
The first immunoprecipitation step using anti-PSG1 antibodies performs a preliminary concentration of fetal-originated EVs-EXs before the second purification step. This preliminary action reduces the volume and complexity of the sample for the subsequent neuronal-specific isolation, making it feasible to obtain sufficient quantities of fetal neuronal EVs-EXs for quantitative measurements from non-invasive maternal blood samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables non-invasive, specific, and sensitive isolation of fetal neuronal extracellular vesicles, allowing for real-time monitoring of fetal brain development from the first trimester to birth and predicting the likelihood of developmental disabilities.
Implementation Method 1
The two-step procedure involves first using an antibody against pregnancy-specific beta-1-glycoprotein 1 (PSG1) to isolate fetal-originated EVs-EXs from placental syncytiotrophoblasts
Implementation Method 2
a second antibody is used to purify neuronal EVs-EXs from the placental EVs-EXs. This antibody is specifically against SV2B, a member of the synaptic vesicle proteins 2 (SV2) family
Implementation Method 3
Separating the neuronal extracellular vesicles from the placental extracellular vesicles may include adding a beaded resin that binds any biotinylated proteins
Data Source
AI summary
A two-step immunoprecipitation technique for isolating fetal neuronal extracellular vesicles (EVs) including exosomes (EXs). First, an antibody against pregnancy-specific beta-1-glycoprotein 1 (PSG1) is used to isolate fetal-originated EVs-EXs from placental syncytiotrophoblasts to obtain placenta-specific EVs-EXs that are of fetal origin circulating in maternal blood. Next, an antibody of synaptic vesicle glycoprotein 2B (SV2B) is used to purify neuronal EVs-EXs from the placental EVs-EXs. The SV2B-immunoprecipitated EVs-EXs according to the present invention may be used for quantitative measurement to determine synaptic function and synapse development, which are related to brain developmental disabilities.